[{"id":"8006740b-2d06-4b2c-ab89-24e67ff05c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT05420493","created_at":"2022-06-15T15:55:29.040Z","updated_at":"2024-07-02T16:35:24.497Z","phase":"Phase 1","brief_title":"Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05420493","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-01-04"},{"id":"4238dfe2-7874-4915-bc58-0730f4ef3002","acronym":"","url":"https://clinicaltrials.gov/study/NCT04271800","created_at":"2021-01-18T20:45:05.713Z","updated_at":"2024-07-02T16:35:50.207Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT04271800","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"5a30c115-90a7-4e39-940d-438a76a9d2a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04271410","created_at":"2021-01-18T20:45:00.531Z","updated_at":"2024-07-02T16:35:50.323Z","phase":"Phase 1/2","brief_title":"CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT04271410","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive • CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2019","start_date":" 06/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"126c525d-ff50-4c3a-b3b4-35da9de12273","acronym":"","url":"https://clinicaltrials.gov/study/NCT05334823","created_at":"2022-04-19T22:56:51.920Z","updated_at":"2024-07-02T16:36:10.121Z","phase":"Phase 2","brief_title":"A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","source_id_and_acronym":"NCT05334823","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD19 • IL6","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2022-05-20"},{"id":"5b21a1ae-4d1e-4951-894b-5e6f9257085c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04888468","created_at":"2021-05-17T18:56:01.624Z","updated_at":"2024-07-02T16:36:15.133Z","phase":"Phase 1","brief_title":"Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents","source_id_and_acronym":"NCT04888468","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD19 • IL6","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 06/29/2021","primary_completion_date":" 06/29/2021","study_txt":" Completion: 09/01/2021","study_completion_date":" 09/01/2021","last_update_posted":"2022-03-18"},{"id":"b9486d1b-373e-4d09-96a8-803459c2e9ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT04888442","created_at":"2021-05-17T18:56:01.210Z","updated_at":"2024-07-02T16:36:30.164Z","phase":"Phase 1","brief_title":"Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL","source_id_and_acronym":"NCT04888442","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD19 • IL6","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • puzolcabtagene autoleucel (pCAR-19B)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 01/30/2022","primary_completion_date":" 01/30/2022","study_txt":" Completion: 03/28/2022","study_completion_date":" 03/28/2022","last_update_posted":"2021-05-17"}]